Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Today, Benzinga 's options scanner spotted 10 uncommon options trades for Abbott Laboratories. This isn't normal. The overall ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Products include pacemakers ... Having examined the options trading patterns of Abbott Laboratories, our attention now turns directly to the company. This shift allows us to delve into its ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

A St. Louis judge has granted a new trial in a case Abbott Laboratories won in the fall, in which a mother alleged that the company’s cow’s milk-based products for premature infants ...